Background: Reductions in adjuvant chemotherapy dose ,85% for historical regimens (ie, cyclophosphamide/methotrexate/fluorouracil) are known to affect breast cancer survival. This threshold, in addition to early versus late dose reductions, are poorly defined for third-generation anthracycline/taxane-based chemotherapy. In patients with breast cancer receiving adjuvant 5-fluorouracil/epirubicin/cyclophosphamide followed by docetaxel (FEC-D), we evaluated the impact of chemotherapy total cumulative dose (TCD), and early (FEC) versus late (D only) dose reductions, on survival outcomes. Patients and Methods: Women with stage I-III, hormone receptor-positive/negative, HER2-negative breast cancer treated with adjuvant FEC-D chemotherapy from 2007 through 2014 in Alberta, Canada, were included. TCD for cycles 1 to 6 of ,85% or $85% was calculated. Average cumulative dose was also calculated for early (cycles 1-3) and late (cycles 4-6) chemotherapy. Survival outcomes (disease-free survival [DFS] and overall survival [OS]) were estimated using Kaplan-Meier and multivariate analysis. Cohorts were evaluated for uniformity. Results: Characteristics were reasonably balanced for all cohorts. Overall, 1,302 patients were evaluated for dose reductions, with 16% being reduced ,85% (n5202) relative to $85% (n51,100; 84%). Patients who received TCD $85% relative to ,85% had superior 5-year DFS (P5.025) and OS (P,.001) according to Kaplan-Meier analysis, which remained significant on univariate and multivariate analyses. In stratified late and early dose reduction cohorts, DFS and OS showed a significant inferior survival trend for dose reduction early in treatment administration in 5-year Kaplan-Meier (P5.002 and P,.001, respectively) and multivariate analyses (hazard ratio [HR], 1.46; P5.073, and HR, 1.77; P5.011, respectively). Dose delays of ,14 or $14 days and granulocyte colony-stimulating factor use did not affect outcomes. Conclusions: Chemotherapy TCD ,85% for adjuvant FEC-D affects breast cancer survival. Late reductions (D only) were not shown to adversely affect DFS or OS. Conversely, early reductions (FEC6D) negatively affected patient outcomes.
Background
Treatment of early-stage breast cancer with adjuvant chemotherapy has improved survival. Landmark metaanalyses by the Early Breast Cancer Trialists' Collaborative Group (EBCTCG) initially showed a 20% to 25% relative risk reduction in breast cancer mortality for first-generation regimens (ie, cyclophosphamide/ methotrexate/fluorouracil [CMF] ) and increased benefit with the addition of anthracyclines and taxanes. 1 Although some meta-analyses have shown the benefits of dose-dense regimens, 2 others have questioned the appropriateness of comparator arms, citing inferior taxane dosing schedules (paclitaxel given every 3 weeks) as potential confounders. 3 Further limiting conclusions are reductions in absolute chemotherapy dose (mg/m 2 ) and cycle delay, shown to affect survival. [4] [5] [6] [7] Historically, reductions in cumulative dose intensity for chemotherapy (average dose across a given regimen) for first-and second-generation regimens (ie, cyclophosphamide/doxorubicin/5-fluorouracil [CAF], 5-fluorouracil/epirubicin/cyclophosphamide [FEC] ) have shown inferior survival in both prospective [8] [9] [10] and select retrospective 11, 12 studies. In a landmark publication, Bonadonna et al 8 showed superior survival for women receiving $85% of the optimal (total cumulative) dose of CMF relative to those receiving ,85%. Similar dose-response relationships were shown in the CALGB 8541 trial using CAF. 13 Further studies aimed at optimizing dose of anthracyclines have shown conflicting data, 14, 15 whereas cyclophosphamide escalation did not lead to improved outcomes. 16, 17 These results are informative but require updating as CMF, CAF, and FEC are inferior to third-generation chemotherapy regimens currently used in the adjuvant setting. Results of retrospective analysis evaluating the effect of chemotherapy dose reduction have been mixed due to a heterogeneity in regimen selection, lack of adjustment for confounding variables, and inadequate follow-up to determine effect. 18, 19 Evaluation of docetaxel dose reductions have also yielded conflicting results. 20, 21 Currently, a paucity of data exists for dose adjustments affecting survival for third-generation anthracycline/taxane-based regimens. Furthermore, for sequential regimens, survival effects of early (ie, anthracycline 6 taxane) versus late (taxane only) dose reductions have not yet been fully characterized.
This retrospective study investigated the effect of chemotherapy total cumulative dose (TCD) using historical thresholds of ,85% or $85% on breast cancer outcomes in women diagnosed with stage I-III, hormone receptor-positive/negative, HER2-negative breast cancer treated with adjuvant FEC for 3 cycles followed by docetaxel (D) for 3 cycles (FEC-D) chemotherapy from 2007 through 2014 in Alberta, Canada. The effects of early (FEC6D) versus late (D only) dose reduction were also explored. 
Patients and Methods

Study Population and Data Collection
TCD Cohorts
Total dose for cycles 1 to 6 were averaged to calculate TCD for the entire FEC-D regimen (Figure 1 ). If a cycle was missed, a value of 0% was assigned for that cycle and included in the overall TCD calculation. Historical TCD levels of ,85% or $85% were evaluated. TCD cohorts are outlined in Figure 2A .
Early Versus Late Cumulative Dose Reduction Cohorts
Total dose for FEC cycles 1 through 3 were averaged to calculate early cumulative dose (ECD), and total dose for cycles 4 through 6 were averaged to calculate late cumulative dose (LCD). To explore the potential effects of ECD 6 LCD reduction versus LCD reduction alone, we first considered 3 cohorts: full-dose FEC-D, any FEC 6 any D reduction (ECD), and full-dose FEC (FEC5100%) 1 any D reduction (LCD). Because survival outcomes for the fulldose and LCD cohorts were equivalent, and those for ECD were inferior to both (supplemental eFigure 1 and eTable 1, available with this article at JNCCN.org), the impact of docetaxel reduction was assessed using the $85% or ,85% cutpoint for patients who had full-dose FEC and those who had any reduction in FEC. Hence, the final analysis considered 4 cohorts ( Figure 2B ): FEC,100%/ D$85% (ECD1), FEC,100%/D,85% (ECD2), FEC5100%/ D$85% (LCD1), and FEC5100%/D,85% (LCD2).
Statistical Methods
Patient, breast cancer, and treatment characteristics were compared using chi-square, Mann-Whitney U, or Kruskal-Wallis H tests where appropriate. For survival calculations, time from definitive breast cancer surgery to last follow-up or event (ie, locoregional or distant recurrence, death) was used. Disease-free survival (DFS) and overall survival (OS) were estimated using the Kaplan-Meier method and compared with log-rank analyses. For the early (ECD1/ECD2) and late (LCD1/ LCD2) dose reduction cohorts, the Holm-Sidak method was used for pairwise comparison to identify survival differences between groups. To evaluate for potential independent effects of TCD or timing of dose reduction (ECD/LCD) while controlling for known prognostic factors, the Cox proportional hazards model was used. Hazard ratios (HRs) and 95% confidence intervals are reported. For all tests, P,.05 was considered significant. Statistics were performed using SigmaPlot V13.0 (Systat Software, Inc.) or SPSS Statistics, version 19 (IBM Corp.).
Results
Patient Eligibility, Selection, and Follow-Up A total of 1,345 patients were assessed for having received FEC-D chemotherapy in the adjuvant setting; 16 patients were excluded for receiving only the FEC (cycles 1-3) portion of chemotherapy and 27 were excluded for receiving nonstandard regimens (eg, FEC-CMF). A total of 1,302 patients were eligible for allocation in the TCD ( Figure 1A ) and early (ECD1/2) versus late (LCD1/2) cumulative dose reduction ( Figure 1B) analyses. Median follow-up was 59.9 months (range, 6.4-122.0 months).
TCD Cohorts
Patient Characteristics
More patients received chemotherapy TCD $85% (n51,100) versus ,85% (n5202) ( Table 1) , and those with a TCD $85% were more likely to be younger (median age, 54 vs 57 years; P,.001) and premenopausal (44.5% vs 28.2%; P#.001), and have a lower number of comorbidities (uCCI score 0; 84.5%) compared with those with a TCD ,85% (72.8%).
Of the pathologic features evaluated, only tumor grade was found to be significantly different between cohorts (P5.014), with the difference likely due to the higher proportion of grade 1 tumors seen in the TCD $85% cohort (9.7% vs 3.5%). No significant differences were seen for other pathologic features associated with recurrence risk (ie, hormone receptor negativity, lymphovascular invasion, AJCC-6 stage, large tumors [T3], and nodal status). Additionally, no significant differences were noted for type of surgery performed, receipt of G-CSF, or chemotherapy dose delays of ,14 days relative to $14 days. As expected, receipt of 4 or 5 cycles of chemotherapy was more commonly associated with a TCD ,85% (P,.001).
Survival Outcomes
Evaluation of TCD thresholds of $85% versus ,85% showed superior DFS at 5 years (85.9% vs 79.2%; P5.025) and superior OS at 5 years (88.8% vs 80.7%; P,.001) (Figure 3 ). Inferior DFS for TCD ,85% relative to $85% was seen in univariate analysis (HR, 1.47; P,.026) and after correction in multivariate analysis (HR, 1.45; P5.040) (supplemental eTable 2). This trend persisted for OS in both univariate (HR, 1.80; P5.001) and multivariate analyses (HR, 1.50; P5.043) (supplemental eTable 3).
ECD and LCD Cohorts
Patient Characteristics Most patients were allocated to the FEC5100%/D$85% group (LCD1; n5791) compared with the FEC5100%/ D,85% (LCD2; n5273), FEC,100%/D$85% (ECD1; n5109), or FEC,100%/D,85% groups (ECD2; n5129). The distribution of early (FEC6D) and late (D only) dose reductions are shown in Figure 4 . Slight differences in age (P,.001) and premenopausal status (P5.002) were noted between cohorts (Table 2 ). More patients in the LCD1 cohort had a uCCI score of zero (86.2%) relative to the LCD2 (77.3%), ECD1 (74.3%), and ECD2 cohorts (79.8%) (P5.002). No significant differences were seen between pathologic features associated with recurrence risk. With respect to treatment, no significant differences were seen for surgical type or chemotherapy dose delays $14 days. Slightly more patients received G-CSF in the LCD2 (21.2%) cohort compared with the LCD1 (14.4%), ECD1 (18.3%), or ECD2 cohorts (14.0%) (P5.033). As expected, receipt of only 4 or 5 cycles of chemotherapy was more commonly associated with the LCD2 (8.4% and 10.6%, respectively) and ECD2 cohorts (8.5% and 9.3%, respectively) compared with the LCD1 and ECD1 cohorts (all 0%) (P,.001).
Survival Outcomes
DFS was significantly different across the 4 cohorts (P5.002; Figure 5A ). At 5 years, DFS was higher in the LCD cohorts: 85.5% for LCD1, 87.2% for LCD2, 78.9% for ECD1, and 75.2% for ECD2. OS was also significantly different across the cohorts (P,.001; Figure 5B ), and was similarly higher at 5 years in the LCD cohorts: 90.0% for LCD1, 87.9% for LCD2, 83.5% for ECD1, and 75.2% for ECD2. 
Discussion
This study evaluated the impact of chemotherapy dose reduction on breast cancer outcomes for a commonly used third-generation anthracycline/taxane-based regimen. Similar to findings of Bonadonna et al, 8 cumulative chemotherapy dose ,85% was shown to negatively affect survival in patients treated with FEC-D. This finding supports the notion that even with the addition of taxanes, sustaining total chemotherapy dose $85% is important for maintaining clinical benefit.
We also evaluated early (FEC6D) relative to late (D only) reductions in chemotherapy dose. Interestingly, worse survival trends were seen in the ECD (FEC,100%/ D$85% and FEC,100%/D,85%) versus LCD cohorts (FEC5100%/D$85% and FEC5100%/D,85%). These data suggest that late reductions in chemotherapy may not have as much of an impact on DFS and OS compared with early reductions. This finding is not completely unexpected, as variability exists in maximally tolerated dose of D, the recommended phase II dose in early-phase clinical trials, 23 27, 28 raising the question of balancing efficacy with toxicity. In the PANTHER study by Foukakis et al, 7 patients who underwent leukocyte nadir, dose-tailored, adjuvant dosedense EC-D every 2 weeks (8 cycles) compared with standard 3-weekly FEC-D (6 cycles) chemotherapy were found to have similar 5-year OS rates (92.1% vs 90.2%; P5.09), despite the superiority of dose-dense regimens. 2, 3, 29 This finding reinforces that lower cumulative dose and early dose reductions likely have a negative impact on survival outcomes.
Our findings highlight the need to avoid chemotherapy dose reductions, particularly early in treatment. Due to the retrospective limitations of our study, it is difficult to accurately evaluate the reasons for dose reduction. Early dose reductions may be related to dose capping for high BSA relating to obesity and concern regarding patient tolerance (ie, comorbidities). Almost one-fifth of the patients in this study had an early dose reduction for the first or subsequent cycles of FEC. In an evaluation of relative dose intensity (RDI) among 190 community oncology practices, Shayne et al 30 identified significant predictors of chemotherapy dose reduction, including BSA .2 m 2 , age $65 years, febrile neutropenia, and comorbidities (particularly renal disease). In other retrospective studies, obesity has been associated with a higher likelihood of upfront dose reduction, affecting event-free survival. 13 In an evaluation of dose-dense chemotherapy tailoring using BSA as a secondary endpoint among patients with breast cancer, Matikos et al 31 showed improved relapse-free survival relative to standard chemotherapy dosing, but only in obese patients.
We hypothesize that some early dose reductions among our study population were likely related to dose capping, at least before 2012 when ASCO guidelines recommended full weight-based chemotherapy doses in the treatment of obese patients. 32 Although our study did not account for BSA or performance status, it was able to examine the impact of comorbidities. Not surprisingly, patients in the LCD1 cohort (FEC5100%/D$85%) had the most favorable comorbidity profile. However, early dose reduction (FEC,100%/D,85% relative to FEC5100%/ D$85%) and comorbidity (uCCI .2 relative to uCCI 0) persisted as significant predictors of worse OS in multivariate analysis.
Early or late dose reductions may be related to toxicity, including febrile neutropenia, and may be associated with dose delay (and consequently lower RDI) with secondary use of G-CSF. Of the entire study population, approximately 16% experienced a dose delay of $14 days. Although we did not specifically calculate RDI (mg/m 2 /wk), chemotherapy delays (,14 or .14 days) did not affect breast cancer survival outcomes in univariate or multivariate analyses. Similarly, of the entire study population, 16% received G-CSF, and use was not significantly associated with DFS or OS. This interpretation is limited, however, as the reason for G-CSF administration (primary vs secondary prophylaxis) and number of cycles received were not recorded. In early versus late multivariate analysis for OS, nodal status $N2 
Conclusions
Among women with stage I-III breast cancer treated with the third-generation FEC-D regimen in the adjuvant setting, chemotherapy TCD ,85% versus $85% affects survival outcomes, and early (FEC6D) relative to late Abbreviations: D, docetaxel; ER, estrogen receptor; FEC, 5-fluorouracil/epirubicin/cyclophosphamide; G-CSF, granulocyte colony-stimulating factor; HR, hazard ratio; OS, overall survival; PR, progesterone receptor; TCD, total cumulative dose; uCCI, updated Charlson comorbidity index. *Significant for P,.05.
